**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 62540

**Manuscript Type:** CASE REPORT

**Therapeutic effect of autologous concentrated growth factor on lower-extremity chronic refractory wounds: A case report**

Liu P *et al*. CGF on chronic refractory wounds

Po Liu, Yang Liu, Chang-Neng Ke, Wei-Shan Li, Yue-Ming Liu, Shi Xu

**Po Liu, Yang Liu, Chang-Neng Ke, Wei-Shan Li, Yue-Ming Liu, Shi Xu,** Department of Burn and Plastic Surgery, Shenzhen Longhua District Central Hospital, Shenzhen 518110, Guangdong Province, China

**Author contributions:** Liu P and Liu Y collected the clinical data, reviewed the literature, and contributed to manuscript drafting; Ke CN and Li WS collected the clinical data; Liu YM and Xu S directed and corrected the study; Liu P and Liu Y contributed equally to this work; all the authors read and approved the manuscript for publication.

**Supported by** Shenzhen Longhua District Science and Innovation Bureau for Key Laboratory Construction, No. 20160919A0410022; and Shenzhen Longhua District Science and Innovation Bureau Fund for Medical Institutions, No. 2020038 and No. 2017136.

**Corresponding author: Shi Xu, PhD, Associate Professor,** Department of Burn and Plastic Surgery, Shenzhen Longhua District Central Hospital, No. 187 Guanlan Avenue, Longhua District, Shenzhen 518110, Guangdong Province, China. xushi\_cn@163.com

**Received:** January 20, 2021

**Revised:** March 29, 2021

**Accepted:** April 20, 2021

**Published online:** June 26, 2021

**Abstract**

BACKGROUND

Management of chronic refractory wounds is one of the toughest clinical challenges for surgeons. Because of poor blood supply, less tissue coverage, and easy exposure, the lower leg is a common site for chronic refractory wounds. The current therapeutic regimens often lead to prolonged hospital stay and higher healthcare costs. Concentrated growth factor (CGF) is a novel blood extract that contains various growth factors, platelets, and fibrins to promote wound healing process. However, there has been little research reported on the treatment of lower extremity wounds with CGF.

CASE SUMMARY

A 37-year-old man, without any past medical history, presented an ulcerated chronic wound on his right lower leg. The skin defect exhibited clear boundaries, with a size of 2.0 cm × 3.5 cm. The depth of wound was up to the layer of deep fascia. *Staphylococcus aureus* was detected by bacterial culture. The final diagnosis was right lower extremity ulcers with infection. Cefathiamidine, silver sulfadiazine, and mupirocin cream were applied to control the infection. CGF gel was prepared from the patient’s blood sample, and was used to cover the wound after thorough debridement. The skin wound was successfully healed after three times of CGF treatment.

CONCLUSION

CGF displays an excellent wound healing promoting effect in patients with lower-extremity chronic refractory wounds.

**Key Words:** Concentrated growth factors; Chronic refractory wounds; Lower extremity; Ulcer; Wound healing; Case report

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Liu P, Liu Y, Ke CN, Li WS, Liu YM, Xu S. Therapeutic effect of autologous concentrated growth factor on lower-extremity chronic refractory wounds: A case report. *World J Clin Cases* 2021; 9(18): 4797-4802

**URL:** https://www.wjgnet.com/2307-8960/full/v9/i18/4797.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v9.i18.4797

**Core Tip:** The effects of the current interventions, such as flap reconstruction, artificial dermis grafting, and negative pressure wound therapy, on chronic refractory wounds may vary among different patients. Concentrated growth factor (CGF) is obtained from the patient’s blood sample, and has a significant amount of growth factors. Here, we report a male patient with lower-extremity wound defects who received CGF treatment. The patient recovered well after three times of CGF treatment. This case highlights the beneficial effect of CGF on chronic wound and provides a novel therapeutic option for lower-extremity refractory wound repair.

**INTRODUCTION**

Chronic refractory wounds are termed as the wounds that do not proceed through an orderly and timely repair to form anatomic and functional integrity within 3 mo. The main causes of refractory wounds include vascular insufficiency, diabetes mellitus, and local pressure effects. Besides, systemic factors such as poor nutritional condition, infection, and altered immunological status also delay the wound healing process[1]. Currently, the management strategies for skin defects, including flap reconstruction, artificial dermis grafting, and negative pressure wound therapy[2,3], still need further optimization. Therefore, it is of utmost urgency to develop new therapeutic options for achieving better clinical outcomes.

As a new-generation biomaterial, concentrated growth factor (CGF) is derived from autologous fresh whole blood by differential centrifugation[4]. CGF is known to contain abundant platelets, fibrins, and growth factors, such as epidermal growth factor, fibroblast growth factor (FGF), insulin-like growth factor, platelet-derived growth factor, transforming growth factor beta 1, and vascular endothelial growth factor[5]. Increasing evidence has demonstrated the multiple effects of CGF on cell growth, migration, vascularization, and tissue transplantation. Previous studies have reported that CGF exhibits the potential for Schwann cell proliferation, dental pulp stem cell regeneration, and bone reconstruction[6-8]. Besides, CGF could increase the success rate of fat grafting by improving the vascularization of the transplanted fat tissue[5]. Therefore, CGF is a promising agent for promoting the growth and regeneration of skin tissue, but very few adequate studies have been conducted to determine its effects on lower-extremity chronic refractory wounds.

**CASE PRESENTATION**

***Chief complaints***

A 37-year-old man, who was admitted to our hospital on July 2, 2017, presented an ulcerated wound on his right lower leg.

***History of present illness***

Two weeks before admission, the patient was exposed to trauma by accident. The improper treatment led to an ulcerated wound on his right lower leg.

***History of past illness***

The patient was free from other illnesses.

***Personal and family history***

The patient had no special personal and family history.

***Physical examination***

Physical examination showed no significant abnormalities. His blood pressure was 125/74 mmHg, pulse was 93 beats per minute, and temperature was 36.3 °C.

***Laboratory examinations***

Upon admission, a routine blood test revealed the following values: Hemoglobin, 167 g/L; white blood cell count, 8.69 × 109/L; red blood cell count, 5.30 × 1012/L; and thrombocytes, 185 × 109/L. Drug susceptibility testing showed that the wound was infected with *Staphylococcus aureus*.

***Imaging examinations***

No imaging examinations were performed as the patient displayed good conditions except the wound on his lower leg.

**FINAL DIAGNOSIS**

The patient was diagnosed as having a right lower-extremity chronic refractory wound, along with *Staphylococcus aureus* infection.

**TREATMENT**

Wound secretion culture and drug sensitivity test were carried out after admission. Transparent graph paper was employed to measure the wound size. Vessel forceps was used to assess the depth of the wound. A thorough mechanical debridement accompanying with Moist Exposed Burn Ointment (MEBO) was performed to remove necrotic tissue. All surgical procedures were conducted under aseptic conditions according to the local policy. Povidone iodine (0.5%) or H2O2 (3%) solution was used to rinse the wound once a day, while mupirocin or silver sulfadiazine ointment was employed after wound dressing until the necrotic tissue and wound exudate were decreased significantly, which were essential for the following procedures. The dressing materials, such as gauze with or without vaseline, were replaced once a day. The interval of wound refilling was dependent on CGF dissolution, typically ranging from 5 d to 7 d.

Autologous venous blood (9 mL) was collected into a sterile Vacuette tube with no additives, and immediately centrifuged using a fixed-program device (Silfradent, Italy). The detailed centrifugation settings are as follows: Acceleration (30 s), 2700 rpm for 2 min, 2400 rpm for 4 min, 2700 rpm for 2 min, and deceleration (30 s). CGF gel was suspended in the middle layer in the Vacuette tube and placed on gauze by forceps. The gel was applied onto the wound, and the dressing was replaced daily. The CGF clots were pressed gently in order to fill the wound space and prevent wound fluid effusion.

The ulcerated wound exhibited clear boundaries, with a size of 2.0 cm × 3.5 cm. The depth of wound was up to the layer of deep fascia. A sinus tract, around 2 cm in length, was extended to the periosteum of the tibia. Besides, necrotic tissues and light yellow liquid effusions were observed inside the wound bed during admission (Figure 1A). Moreover, the condition of the wound bed was poor, and a small amount of granulation tissue was found. Symptoms such as slight redness, swelling, and pain were also present near the wound site. Cefathiamidine, silver sulfadiazine, and mupirocin cream were applied to control infection, as *Staphylococcus aureus* was detected by bacterial culture. The periosteum was exposed after thorough debridement and MEBO application (Figure 1B). The formation of granulation tissue was enhanced by recombinant bovine basic FGF. The ulcerated wound was successfully covered by CGF gel (Figure 1C), and the wound closure showed an encouraging trend after CGF treatment. The wound cavity was thinner and wound bed was smaller on postoperative days 11 and 17 after CGF treatment, respectively (Figure 1D and E). The wound site was refilled once the CGF gel was degraded. After three times of CGF treatment, the skin wound was healed (Figure 1F).

**OUTCOME AND FOLLOW-UP**

Encouraging results were obtained by CGF intervention, even in the infected wound. As mentioned above, the skin defect was successfully healed after three times of CGF treatment. The patient was discharged on August 1 and no medication was needed throughout the whole follow-up period.

**DISCUSSION**

Wound healing is a complex process involving the interactions among cells, extracellular matrix, and cytokines. The normal skin repair process is characterized by inflammatory responses, granulation tissue formation, re-epithelialization, stromal cell production, and tissue remodeling[9]. Currently, there are no well-established and widely accepted guidelines for the clinical management for chronic wound due to its complicated pathogenesis and no satisfactory treatment strategies in the clinical settings. Several factors have been identified to affect the healing process of a chronic wound. Insufficient growth factors generally retard cell proliferation, thereby leading to chronic or non-healing wounds[10]. Therefore, improving the growth factor content may be a promising approach for chronic wound management.

CGF is a new-generation whole blood extraction following the platelet-rich plasma and platelet-rich fibrin[11]. As a bio-scaffold and reservoir of growth factors, CGF has been applied in bone regeneration and dental implantation[12]. The abundance of growth factors is beneficial for cell proliferation, vascularization, and tissue remodeling. It has been reported that CD34 positive cells, which play essential roles in mediating inflammation and revascularization, were enriched in CGF gel[13]. Besides, the unique three-dimensional structure of fibrin network provides excellent conditions for the slow release of growth factors and cell proliferation. The characteristics of soft texture and elastic shape are the distinguishing features for CGF application.

Chronic refractory wound on the lower leg is a common physical trauma that occurs after surgical procedures. Although only one representative case was reported in this study, we collected the data of 56 cases with non-healing wounds on their lower extremity and good outcomes were achieved after CGF treatment. Several clinical experiences with respect to the management of wound care are warranted. First, aggressive treatment is essential for primary disease. For example, nutritional support therapy is favorable for those patients with poor physical health, while patients with lower extremity varicose veins should pay more attention to venous stasis. Patients with nodular vasculitis need to receive hormone systemic therapy in order to reduce autoimmune response. For patients with limited physical mobility, suspended bed is helpful to relieve the compression in order to reduce local tissue damage. Second, preparing the wound bed is the foundation of treatment. Most of the wounds showed local infection, therefore, antibiotics should be used cautiously during CGF treatment. Topical ointment was sufficient to control the disease progression if there are no symptoms and signs of systemic infection. Mupirocin ointment is preferred for *Staphylococcus aureus* infection, while silver sulfadiazine ointment is preferred for *Pseudomonas aeruginosa* infection. Due to the thin subcutaneous tissue on lower extremity, excessive debridement should be avoided otherwise it may lead to wound bed deterioration and bone exposure. Therefore, proper wound treatment including debridement and antibiotics indeed facilitated wound healing in clinical practice. Third, the appropriate dose of CGF gel is the key of treatment. For patients with bone or periosteum exposure, the CGF gel should be thick enough to maintain a moist wound environment and prevent tissue necrosis. For patients with a sinus tract, CGF gel should be firmly filled in the cavity to minimize the risk of infection. Dressing is also an important factor in successful CGF application. Vaseline gauze can serve as the outer layer of dressing to prevent CGF shifting. During the dressing change, removal of wound exudate may help promote the wound healing process.

CGF is a novel biomaterial that holds great promise for applications in tissue repair and regeneration, but several shortcomings exist as well. Lack of negative control, proper wound treatment might play an important role in CGF therapy on lower-extremity chronic refractory wounds. Moreover, the high demand for blood sample is the main limitation of CGF application in clinical practice, especially for skin defect patients with poor physical health. Besides, the storage of CGF is another challenging issue for its application, as a specific device is needed and CGF has to be used freshly to ensure its biological activity. Therefore, it is necessary to develop CGF-related products for overcoming these problems.

**CONCLUSION**

In conclusion, our study reveals that CGF has an excellent curative effect on lower-extremity chronic refractory wounds. Thus, CGF treatment is worthy of clinical promotion and popularization.

**REFERENCES**

1 **Werdin F**, Tenenhaus M, Rennekampff HO. Chronic wound care. *Lancet* 2008; **372**: 1860-1862 [PMID: 19041788 DOI: 10.1016/S0140-6736(08)61793-6]

2 **Attia A**, Elmenoufy T, Atta T, Harfoush A, Tarek S. Combination of negative pressure wound therapy (NPWT) and integra dermal regeneration template (IDRT) in the lower extremity wound; Our experience with 4 cases. *JPRAS Open* 2020; **24**: 32-39 [PMID: 32322648 DOI: 10.1016/j.jpra.2020.03.004]

3 **Seth AK**, Friedstat JS, Orgill DP, Pribaz JJ, Halvorson EG. Microsurgical Burn Reconstruction. *Clin Plast Surg* 2017; **44**: 823-832 [PMID: 28888307 DOI: 10.1016/j.cps.2017.05.014]

4 **Topkara A**, Özkan A, Özcan RH, Öksüz M, Akbulut M. Effect of Concentrated Growth Factor on Survival of Diced Cartilage Graft. *Aesthet Surg J* 2016; **36**: 1176-1187 [PMID: 27590866 DOI: 10.1093/asj/sjw137]

5 **Hu Y**, Jiang Y, Wang M, Tian W, Wang H. Concentrated Growth Factor Enhanced Fat Graft Survival: A Comparative Study. *Dermatol Surg* 2018; **44**: 976-984 [PMID: 29894435 DOI: 10.1097/DSS.0000000000001337]

6 **Qin J**, Wang L, Sun Y, Sun X, Wen C, Shahmoradi M, Zhou Y. Concentrated growth factor increases Schwann cell proliferation and neurotrophic factor secretion and promotes functional nerve recovery in vivo. *Int J Mol Med* 2016; **37**: 493-500 [PMID: 26709397 DOI: 10.3892/ijmm.2015.2438]

7 **Xu F**, Qiao L, Zhao Y, Chen W, Hong S, Pan J, Jiang B. The potential application of concentrated growth factor in pulp regeneration: an *in vitro* and *in vivo* study. *Stem Cell Res Ther* 2019; **10**: 134 [PMID: 31109358 DOI: 10.1186/s13287-019-1247-4]

8 **Mirković S**, Djurdjević-Mirković T, Pugkar T. Application of concentrated growth factors in reconstruction of bone defects after removal of large jaw cysts--the two cases report. *Vojnosanit Pregl* 2015; **72**: 368-371 [PMID: 26040184 DOI: 10.2298/vsp1504368m]

9 **Wang PH**, Huang BS, Horng HC, Yeh CC, Chen YJ. Wound healing. *J Chin Med Assoc* 2018; **81**: 94-101 [PMID: 29169897 DOI: 10.1016/j.jcma.2017.11.002]

10 **Qing C**. The molecular biology in wound healing & non-healing wound. *Chin J Traumatol* 2017; **20**: 189-193 [PMID: 28712679 DOI: 10.1016/j.cjtee.2017.06.001]

11 **Kim TH**, Kim SH, Sándor GK, Kim YD. Comparison of platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and concentrated growth factor (CGF) in rabbit-skull defect healing. *Arch Oral Biol* 2014; **59**: 550-558 [PMID: 24667430 DOI: 10.1016/j.archoralbio.2014.02.004]

12 **Pirpir C**, Yilmaz O, Candirli C, Balaban E. Evaluation of effectiveness of concentrated growth factor on osseointegration. *Int J Implant Dent* 2017; **3**: 7 [PMID: 28258471 DOI: 10.1186/s40729-017-0069-3]

13 **Rodella LF**, Favero G, Boninsegna R, Buffoli B, Labanca M, Scarì G, Sacco L, Batani T, Rezzani R. Growth factors, CD34 positive cells, and fibrin network analysis in concentrated growth factors fraction. *Microsc Res Tech* 2011; **74**: 772-777 [PMID: 21780251 DOI: 10.1002/jemt.20968]

**Footnotes**

**Informed consent statement:** Written informed consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest to report.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** January 20, 2021

**First decision:** March 25, 2021

**Article in press:** April 20, 2021

**Specialty type:** Dermatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Jun YM **S-Editor:** Liu M **L-Editor:** Wang TQ **P-Editor:** Liu JH

**Figure Legends**



**Figure 1 A 37-year-old man suffered from traumatic injury, and presented an ulcerated wound on his right lower leg.** A: The condition of the wound bed during admission; B: The periosteum was exposed after thorough debridement; C: Concentrated growth factor (CGF) gel was used to cover the wound; D: The appearance of wound on postoperative day 11 after CGF treatment; E: The skin defect showed a healing trend on postoperative day 17 after CGF treatment; F: The wound was well healed after 21 d of CGF treatment.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**